Publication:
Muscle wasting: emerging pathways and potential drug targets

Simple item page
dc.contributor.departmentDepartment of Molecular Biology and Genetics
dc.contributor.departmentGraduate School of Sciences and Engineering
dc.contributor.kuauthorWaraich, Aylin Domaniku
dc.contributor.kuauthorBilgiç, Şevval Nur
dc.contributor.kuauthorKır, Serkan
dc.contributor.schoolcollegeinstituteCollege of Sciences
dc.contributor.schoolcollegeinstituteGRADUATE SCHOOL OF SCIENCES AND ENGINEERING
dc.date.accessioned2025-01-19T10:30:19Z
dc.date.issued2023
dc.description.abstractMuscle wasting is a serious comorbidity associated with many disorders, including cancer, kidney disease, heart failure, and aging. Progressive loss of skeletal muscle mass negatively influences prognosis and survival, and is often accompanied by frailty and poor quality of life. Clinical trials testing therapeutics against muscle wasting have yielded limited success. Some therapies improved muscle mass in patients without appreciable differences in physical performance. This review article discusses emerging pathways that regulate muscle atrophy, including oncostatin M (OSM) and ectodysplasin A2 (EDA2) receptor (EDA2R) signaling, outcomes of recent clinical trials, and potential drug targets for future therapies.
dc.description.fulltextNo
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessN/A
dc.description.peerreviewstatusN/A
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuTÜBİTAK
dc.description.sponsorshipThis work was supported by the European Molecular Biology Organization (EMBO) installation grant ( #4162 ) and the Scientific and Technological Research Council of Turkey (TUBITAK) grant ( 122Z163 ) to S.K.
dc.description.versionN/A
dc.identifier.doi10.1016/j.tips.2023.07.006
dc.identifier.embargoN/A
dc.identifier.grantno122Z163
dc.identifier.issn0165-6147
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85170227069
dc.identifier.urihttps://doi.org/10.1016/j.tips.2023.07.006
dc.identifier.urihttps://hdl.handle.net/20.500.14288/26036
dc.identifier.wos1149814500001
dc.keywordsCachexia
dc.keywordsSkeletal muscle atrophy
dc.keywordsWasting
dc.language.isoeng
dc.publisherElsevier Ltd
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofTrends in Pharmacological Sciences
dc.relation.openaccessN/A
dc.rightsN/A
dc.subjectPharmacology and pharmacy
dc.titleMuscle wasting: emerging pathways and potential drug targets
dc.typeReview
dspace.entity.typePublication
local.contributor.kuauthorWaraich, Aylin Domaniku
local.contributor.kuauthorBilgiç, Şevval Nur
local.contributor.kuauthorKır, Serkan
relation.isGoalOfPublicationa9786601-9431-4553-9a46-013bb366fb87
relation.isGoalOfPublication.latestForDiscoverya9786601-9431-4553-9a46-013bb366fb87
relation.isOrgUnitOfPublicationaee2d329-aabe-4b58-ba67-09dbf8575547
relation.isOrgUnitOfPublication3fc31c89-e803-4eb1-af6b-6258bc42c3d8
relation.isOrgUnitOfPublication.latestForDiscoveryaee2d329-aabe-4b58-ba67-09dbf8575547
relation.isParentOrgUnitOfPublicationaf0395b0-7219-4165-a909-7016fa30932d
relation.isParentOrgUnitOfPublication434c9663-2b11-4e66-9399-c863e2ebae43
relation.isParentOrgUnitOfPublication.latestForDiscoveryaf0395b0-7219-4165-a909-7016fa30932d

Files

Collections

Publications without Fulltext